UBS: Maintains "Buy" rating on WuXi Biologics (02269), target price HK$62

Zhitong Finance APP has learned that UBS released a research report stating that WuXi Biologics (02269) has entered into an exclusive cooperation agreement with German healthcare company Fresenius, obtaining the developer et rights for 37 biosimilars over the next ten years. This move is seen as recognition of the company's R&D strength. The "Buy" rating is maintained, with a target price of HK$62.